Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market ...

Their success is attributed to two of the first PD-1 inhibitors to be approved, Keytruda (pembrolizumab) and Opdivo (nivolumab). Ten years on from their approval, GlobalData reviews their market entry ...

Opdivo carries a very high cost in the US – $12,500 a month or $150,000 for patients who stay on the drug for a year, but BMS is likely to offer the drug at a discount on this level in Europe ...

Among patients with advanced melanoma, treatment with Opdivo (nivolumab) with or without Yervoy (ipilimumab) benefited both overall survival (OS, the time a patient lives, regardless of disease status ...

The agency has already approved Keytruda and Opdivo when combined with chemotherapy as a first-line treatment for patients with HER2-negative unresectable or metastatic gastric or gastroesophageal ...

The most notable change is to the company’s logo: what was previously a sans-serif wordmark styled as “Moz://a” has been updated to correctly spell out the Mozilla name, featuring a new ...

What makes a good AI logo? It’s a thorny question that every player in the current crop of leading AI companies has faced, since unlike an email app — which marries neatly with an envelope ...

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo. A treatment combination with Yervoy (ipilimumab) plus ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...

Prior data suggested that using BMS's immune checkpoint inhibitors together — specifically, 1 milligram per kilogram of Opdivo (nivolumab) and 3 milligrams per kilogram of Yervoy (ipilimumab) — could ...

Currently, only approximately 30% of patients who receive Merck & Co., Inc.'s Keytruda® (pembrolizumab) or Bristol Myers Squibb's Opdivo® (nivolumab) will have lasting clinical responses to ...